Jaume Ordi


Country: Spain


  1. Maurel J, Martins A, Poveda A, Lopez Guerrero J, Cubedo R, Casado A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010;116:3692-701 pubmed publisher
    ..Low-dose chemobiotherapy combination showed promising activity in heavily pretreated gastrointestinal sarcoma tumor patients, especially in those with WT-KIT genotype. ..
  2. request reprint
    Maurel J, Buesa J, Lopez Pousa A, del Muro X, Quintana M, Martin J, et al. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). J Surg Oncol. 2004;88:44-9 pubmed
    ..The design of randomized trials in ASTS including HDIF should consider those prognostic factors as stratification variables. ..
  3. Alonso Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Hörndler C, et al. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014;50:1973-81 pubmed publisher
    ..4; 95% CI, 1.2-4.78; p=0.01) in KRAS/BRAF WT mCRC patients. RAC1b overexpression constitutes a marker of poor prognosis in KRAS/BRAF WT mCRC patients treated with first-line FOLFOX/XELOX therapy. ..
  4. request reprint
    Maurel J, Postigo A. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. Curr Cancer Drug Targets. 2015;15:703-15 pubmed
    ..In this review we analyzed how certain biomarkers in tumor cells and microenvironment influence the response to new TA and immune-therapies strategies in mCRC pre-treated patients. ..
  5. Maurel J, Lopez Pousa A, de Las Peñas R, Fra J, Martin J, Cruz J, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol. 2009;27:1893-8 pubmed publisher
    ..88). Overall survival did not differ between the two therapeutic arms (P = .14). Single-agent doxorubicin remains the standard treatment in fit patients with advanced soft tissue sarcoma. ..
  6. Benavides M, Antón A, Gallego J, Gómez M, Jiménez Gordo A, La Casta A, et al. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol. 2015;17:982-7 pubmed publisher
    ..New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease. ..
  7. request reprint
    Maurel J, Nadal C, Garcia Albeniz X, Gallego R, Carcereny E, Almendro V, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121:1066-71 pubmed
    ..In conclusion, MMP-7 is an independent prognostic factor for survival in advanced CRC. In our sample, the risk of death associated to MMP-7 increase is much higher than the risk of death associated to lactate dehydrogenase elevation. ..